Estrogen and Androgen Receptor Inhibitors: Unexpected Allies in the Fight Against COVID-19.
Sara BravacciniEugenio FonziMichela TebaldiDavide AngeliGiovanni MartinelliFabio NicoliniPaola ParrellaMassimiliano MazzaPublished in: Cell transplantation (2021)
Given the COVID-19 coronavirus emergency, a special focus is needed on the impact of this rapidly spreading viral infection on cancer patients. Androgen receptor (AR) signaling in the transmembrane protease serine 2 (TMPRSS2) regulation is emerging as an important determinant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) susceptibility. In our study, we analyzed AR and TMPRSS2 expression in 17,352 normal and 9,556 cancer tissues from public repositories and stratified data according to sex and age. The emerging picture is that some patient groups may be particularly susceptible to SARS-CoV-2 infection and may benefit from antiandrogen- or tamoxifen-based therapies. These findings are relevant to choose proper treatments in order to protect cancer patients from concomitant SARS-CoV-2 contagion and related symptoms and put forward the idea that hormonal therapies could be used as prophylactic agents against COVID-19.
Keyphrases
- sars cov
- respiratory syndrome coronavirus
- coronavirus disease
- healthcare
- poor prognosis
- emergency department
- gene expression
- estrogen receptor
- papillary thyroid
- case report
- type diabetes
- metabolic syndrome
- electronic health record
- depressive symptoms
- young adults
- polycystic ovary syndrome
- positive breast cancer
- childhood cancer
- adverse drug